- Conditions
- Plaque Type Psoriasis
- Interventions
- GP2017 Adalimumab, Humira ® Adalimumab
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 5,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Molluscum Contagiosum
- Interventions
- SB206 10.3% berdazimer, vehicle gel
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 891 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 55
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 51 more
- Conditions
- Vasomotor Symptoms
- Interventions
- desvenlafaxine succinate sustained release, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 55
- States / cities
- Tucson, Arizona • Beverly Hills, California • Encinitas, California + 44 more
- Conditions
- Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
- Interventions
- Orticumab, Placebo
- Drug
- Lead sponsor
- Abcentra
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more
- Conditions
- Presbyopia
- Interventions
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more
- Conditions
- Endometrial Neoplasms
- Interventions
- olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years · Female only
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Concord, California • La Jolla, California + 45 more
- Conditions
- Atopic Dermatitis
- Interventions
- Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
- Conditions
- Type 1 Diabetes
- Interventions
- Teplizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Not listed
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
- Conditions
- Revision Total Knee Arthroplasty
- Interventions
- ATTUNE Revision Knee System in Revision Total Knee Arthroplasty
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 16
- States / cities
- San Diego, California • Denver, Colorado • Fort Collins, Colorado + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 407
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
- Conditions
- Severe Coronary Artery Disease (S-CAD)
- Interventions
- Not listed
- Lead sponsor
- Spirocor
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 25 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 260
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 221 more
- Conditions
- Elective Cardiac Surgery
- Interventions
- CytoSorb
- Device
- Lead sponsor
- CytoSorbents, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 503
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 332 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 317
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Obstructive Sleep Apnea Hypopnea, OSA, OSAH
- Interventions
- Provent Professional Sleep Apnea Therapy Device, Sham Device
- Device
- Lead sponsor
- Ventus Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 17
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Redwood City, California + 14 more
- Conditions
- Cystic Fibrosis
- Interventions
- Docosahexaenoic acid (DHA), Standard formula (Enfamil)
- Dietary Supplement
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- Up to 56 Days
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Element Coronary Stent System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 14
- States / cities
- Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Leflunomide, Methotrexate, Ocrelizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 836 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 144
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Darapladib 160 mg, Placebo, Standard Therapy
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 290
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more